A highly promising field in cancer research is the development of blood tests that can detect different cancers at the earliest stages. Referred to as multi-cancer early detection (MCED), this technology has the potential to become a game-changer for cancer control worldwide. Dr Dan Milner, Executive Director of the Access to Oncology Medicines Coalition (ATOM) explains how MCED works and why he is optimistic that it will help us turn the tide on cancer. Hosted on Acast. See acast.com/privacy for more information.